78 results about "Anti atherosclerosis" patented technology

The present invention relates to the field of medical technology, and in particular relates to a category of novel sulphonyl substituted xanthene ketone compounds that have a structural formula as shown in the right, a preparation method and application thereof. The compound has high inhibitory activity for ACAT1/ACAT2; most of the compounds have high inhibitory activity for acyl coenzyme A cholesterol acyltransferase (ACAT). The compounds can be used for preparing anti-atherosclerosis drug combination. Furthermore, the compounds can be used as a preventive or a treating agent of such diseases as angina, myocardial infarction, cerebral infarction, apoplexy, Alzheimer's disease, acute coronary syndrome, PTCA or restenosis of coronary artery after a bracket is arranged. The compounds can be used as a treating agent to adjust the function of sebaceous glands of the skin and inhibit the excessive generation of sebum. And the compounds can be used for treating such diseases as acne-like damage caused by oily skin, acne, seborrhea and corticosteroids.

The invention relates to application of triacetyl-3-hydroxyphenyladenosine (THPA) in preparing a medicament for treating atherosclerosis. The invention has the advantages of providing new application of the THPA, disclosing and quantitatively analyzing various activities of the THPA on resisting atherosclerosis lesion for the first time, providing new knowledge on the anti-atherosclerosis function of the THPA, and indicating that use of the THPA provides a new treatment strategy for treating the atherosclerosis.

The present invention discloses purposes of artemisinin compounds in preparing anti-atherosclerotic medicaments. The artemisinin compounds are artemisinin, artesunate, dihydroartemisinin or artemether. The artemisinin compounds may be prepared to be any kind of pharmaceutically acceptable preparation. The present invention has exploited new medical purposes of the artemisinin compounds, overcoming the shortages of prior anti-atherosclerosis drugs; treatment effects are brought into play from two ways of anti-inflammatory and lipid-lowering; while the artemisinin compounds are reference listed drugs of China and are mainly produced in China, thus having wide sources, low prices; and the artemisinin compounds have strong pharmacological effects, high security, providing an economical, safe drug selection for the mass patients with cardiovascular diseases.

The invention relates to a manufacturing method of a targeted magnetic nanometer probe for early diagnosis of atherosclerosis vulnerable plaques, which is used for carrying out experiment research for the early warning of vulnerable plaques at an early stage and providing experimental data support for development and popularization of an innovation-type diagnostic reagent, so that not only can unstable plaques be effectively found and pre-warned at the early stage, but also the curative effect of the novel anti-atherosclerosis drug can be evaluated. The manufacturing method disclosed by the invention comprises the following steps of: using Fe3O4 nanometer particles PEI (Polyethyleneimine)-Fe3O4-NP (Nonyl Phenol) of PEI as carriers; and connecting profilin-1 antibodies on the surfaces of the carriers by a chemical synthesis method to form the magnetic nanometer probe PF(Profilin)1-PEI-Fe3O4-NP of the targeted profiling-1 protein.

The invention relates to a ligusticum chuanxiong hort extract and a preparation method and application thereof. The ligusticum chuanxiong hort extract contains 30 to 90 mass percent of ligustilide, and can be used for preparing anti-atherosclerosis medicines or lipid-lowering medicines.

The invention discloses a method for enhancing the content of tanshinone in salvia miltiorrhiza hairy root by double genetic transformation, belonging to methods for enhancing the content of tanshinone in medicinal material salvia miltrorrhiza. Tanshinone substance has a plurality of pharmacological activities like antitumor, bacteria resistance and anti-inflammation, anti-atherosclerosis and thelike, however, the content of tanshinone in salvia miltiorrhiza is so low as not to meet the demand of medical treatment. According to the invention, SmHMGR and SmGGPPS genes are cloned from salvia miltrorrhiza, expression vectors containing the SmHMGR and SmGGPPS genes are constructed, leaves of salvia miltiorrhiza are subjected to genetic transformation to obtain salvia miltiorrhiza hairy root of SmHMGR and SmGGPPS transgenes, the content of tanshinone is determined by semiquantitative RT-PCR analysis and high performance liquid chromatography, and antioxidant activity of tanshinone in trangene hairy root by DPPH free radical scavenging method. The method has the advantages that: the content of tanshinone in trangene salvia miltiorrhiza hairy root is enhanced dramatically; and the cost of salvia miltiorrhiza is low. The production process causes no environmental pollution.

The invention provides a Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases and resisting fatigue, which comprises the following components in part by weight: 30 to 90 parts of glossy ganoderma extract, 40 to 120 percent of notoginseng root extract, 40 to 120 parts of root of red-rooted salvia extract and 40 to 120 parts of ginkgo leaf extract. The Chinese medicinal composition has the effects of regulating blood fat, improving hemorheology and resisting atherosclerosis, anoxia and fatigue, can reduce the level of lactic acid and serum urea and can relieve the discomfort feeling of limb weakness, oscitancy, muscular soreness, anorexia and the like which are caused by sports effectively. The invention also provides a Chinese medicinal preparation containing the Chinese medicinal composition and a preparation method thereof.

The invention discloses a preparation method of pH-sensitive hyaluronic acid nano drug-loading particles targeting atherosclerosis, and belongs to the technical field of new drug preparations. The preparation method comprises the following steps: 1) covalent bonding of a bridging agent having terminal hydrazine groups to hyaluronic acid is carried out to obtain a hyaluronic acid derivative; 2) analdehyde compound containing a hydrophobic chain is grafted to the hyaluronic acid derivative through a terminal hydrazine group to obtain a pH-sensitive hyaluronic acid copolymer containing a hydrazone bond; and 3) a hydrophobic anti-atherosclerosis drug is encapsulated into the hydrophobic core of the pH-sensitive hyaluronic acid copolymer. The invention also discloses pharmaceutical particles thereof. Biodegradable and biocompatible materials are used in the invention, and are metabolized and excreted through normal physiological pathways. The vector has multi-targeting property. By specific binding of Hyaluronic acid to CD44 and Stabilin-2 receptors overexpressed on the atherosclerotic plaque cell surface, the carrier can respond to an acidic inflammatory environment to release the drug and achieve the combined treatment of anti-oxidant drugs and anti-atherosclerosis drugs.

The invention relates to a natural medicine for treating diabetes, which takes American ginseng, Chinese caterpillar fungus, barbary wolfberry fruit, common yam rhizome, sweet potato, corn stigma, pumpkin, bitter gourd and buckwheat as raw materials for the formula, the raw materials are prepared into capsules according to the conventional preparation method, thus having significant effects of regulating normal blood sugar metabolism of the human body, anti-atherosclerosis, enhancing immunity and treating diabetic complications; furthermore, the natural medicine is safe and has no toxicity or side effects.

The invention provides a small peptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the small peptide is shown as SEQ ID NO:1. The invention also provides the application of the small peptide to preparation of functional food for alleviating diabetic complications, anti-atherosclerosis functional food, antioxidant functional food, a free radical scavenging product and a lipid peroxidation inhibition product. The small peptide not only has relatively high antioxidant capability, but also can be used for regulating high glucose-induced abnormal proliferation of VSMCs (vascular smooth muscle cells) and regulating apoptosis of the VSMCs in a high glucose environment to finally make the VSMCs tending to get normal, and thus has a broad development prospect on the aspects of prevention of atherosclerosis formation in the high glucose environment, alleviation of other diabetic complications and the like.

The invention discloses an application of an extract of penthorum Chinense pursh in preparing medicine for treating atherosclerosis or relieving Alzheimer disease. The extract plays a role through inducing autophagy, and four key compounds in the extract are disclosed. The extract of the penthorum Chinense pursh and the compounds thereof exhibit anti-atherosclerosis oxidative stress damage in experiments in vitro and vivo, have inhibiting effect on formation of beta-amyloid fiber and expression of Tao protein and have potential application for treating atherosclerosis and relieving Alzheimer disease.

The invention relates to an antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases, comprising the following components of szechuan lovage rhizome, the root of kudzu vine, Panax notoginsenosides and red yeast rice. The method for preparing phospholipid complex formulation of the antiatherosclerotic Chinese traditional medicincomprises (1) preparation of dry extract of the root of kudzu vine, (2) preparation of szechuan lovage rhizome oil and dry extract of Ligusticum wallichii and (3) preparation of formulation. By enriching effective parts of medicinal materials, the purity of effective components of the antiatherosclerotic Chinese traditional medicine is enhanced greatly, thereby meeting the request of formulation. The invention is formed by trial of medicinal effectiveness separation and innovation of the medicine and realizes organic combination of traditional formulation process and modern pharmaceutical technology, thereby not only enhancing medicine-loading rate but also enhancing bioavailability of medicine used by a human body.

The invention discloses an anti-atherosclerosis drug efficacy evaluation method based on inflammatory responses, wherein the method comprises the following steps: step 1, planting smooth muscle cells on the outer side of a Millicell@insert PE (Poly Ethylene) membrane, and turning after the cells are adhered to the wall for 8 hours; step 2, planting endothelial cells on the inner side of the membrane, and culturing for 6 days totally; step 3, inoculating mononuclear cells THP-1, adding oxLDL, IL-1 and texted drugs, and culturing for 24 hours; step 4, detecting any one of the items of detecting contents of MCP-1 and TNFa in the endothelial cells; detecting the content of CD36 on the surface of the mononuclear cells; detecting the contents of MDA and MMP2 in the smooth muscle cells, observing the change of a smooth muscle cytoskeleton; observing the expression of ICAM-1 of the endothelial cells.

The invention discloses a furoxan NO donor-type statin derivative and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The derivative has the structural formula represented by the following formula: wherein R is an alkyl, R1 is a statin residual group, and R2 is an aryl or an aryl sulfonyl. A statin drug is selected to "hybridize" with a NO donor, both NO and the statin drug have good therapeutic effects on atherosclerosis, and the problem of the mismatch of action mechanisms of NO and the statin drug is effectively avoided. In addition, 4-coumaric acid is selected as a linking group, and thus the therapeutic effect of the drug can be effectively enhanced. The compound can effectively release NO in vitro, and the useful attempt for the development of NO donor anti-atherosclerosis drugs is made.

The invention belongs to the field of anti-arteriosclerosis drugs, and particularly relates to application of a carbonic anhydrase inhibitor to preparation of the anti-arteriosclerosis drugs. The study finds for the first time that carbonic anhydrase 1 (CA1) is highly expressed in arteriosclerosis calcified tissue, and CA1 is related to vascular smooth muscle calcification and affects cell proliferation and apoptosis. Methazolamide, the inhibitor of CA1, can significantly reduce the progression of atherosclerosis and inhibit atherosclerotic inflammatory factors. The results suggest that calcification plays an important role in atherosclerosis, and CA1-dominated calcification promotes the course of the atherosclerosis. Methazolamide has a potential therapeutic effect on the atherosclerosisby inhibiting expression of CA1. The findings not only further explain the close relationship between the atherosclerosis and the calcification, but also explore the calcification mechanism of the atherosclerosis, and further prove that inhibition of the calcification is a key point in the treatment of the atherosclerosis. The application of the carbonic anhydrase inhibitor to the preparation of the anti-arteriosclerosis drugs provides new ideas for the treatment of the atherosclerosis.

The invention discloses an application of alisol A in preparation of anti-atherosclerosis medicaments. Animal tests prove that the alisol A has a significant treatment effect on an arteriosclerosis model of an ApoE-/- mouse which is fed with a high-fat diet and combined with carotid artery injury surgery. The medicament disclosed by the invention has relatively low toxicity and is suitable for long-term use. The invention provides the medicament for treating arteriosclerosis, which has the advantages of exact curative effect, definite ingredients and controllable quality, and can meet the needs of clinical applications, by applying the modern medicine theory. The effect of inhibiting vascular intimal hyperplasia of the ApoE-/- mice after carotid artery injuries, caused by high-fat diets, of the alisol A is firstly disclosed by the invention, thereby showing that the alisol A has an obvious effect on treating the arteriosclerosis.

The invention discloses a multifunctional liposome based on hydrogen peroxide response and a preparation method and application thereof, and belongs to the technical field of nano materials. The multifunctional liposome based on hydrogen peroxide response is jointly composed of phosphatidylserine and biblock polymer polyethylene glycol-polyacrylate propylene; and the preparation method includes the steps of preparation of PEG-PPS and preparation of the multifunctional liposome in response to hydrogen peroxide. The multifunctional liposome based on hydrogen peroxide response is used for coatinga dual-mode probe FITC-SiO2@Fe3O4 and can be used for in-vivo imaging; and the multifunctional liposome based on hydrogen peroxide response is used for coating anti-atherosclerosis drugs and can be used for drug release in vivo. According to the multifunctional liposome based on hydrogen peroxide response and the preparation method and application thereof, biodegradable polyethylene glycol is conjugated to the outer surface of the liposome to produce an invisible carrier, and immune clearance is prevented; and meanwhile, the traditional polyethylene glycol is specially modified, and while biocompatibility is retained and the hydrogen peroxide can be responded to release imaging agents or the drugs.

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

The invention provides a nicotinic acid-containing capsaicin ester derivative with a general structural formula I and a preparation method thereof. The derivative has analgesic, anti-tumor, anti-inflammatory, anti-atherosclerosis, hypolipidemic, appetite promoting, digestion improving, antibacterial and insecticide, anti-oxidant, anti-viral applications.

The invention discloses a viburnum sargentii branch and leaf lignan, an extraction method and application. The extraction method comprises the steps of smashing dried viburnum sargentii branches and leaves, and the like; using a constant-temperature ultrasonic instrument for suspending an extract with warm water, extracting, and decompress concentrating to obtain an extract; dissolving the extract at a cholorform part in methanol, eluting to remove chlorophyll, carrying out chromatography and purification to obtain 5 different compounds. A monomer lignan obtained through the invention has the purity achieving 96 percent to 99 percent, can be subjected to goal-oriented structural modification, and is applied in pharmaceutical synthesis so as to obtain pharmaceutical molecules with better activity; 5 lignans are firstly extracted from viburnum sargentii , so that an approach for obtaining such natural active ingredients is wider. The extraction method provided by the invention is simple and convenient, easy to separate and recover an organic solvent mixture, less in emission, and suitable for modern fine industrial production. The invention adopts a latest SBC MCI GEL reversion phase chromatography filler, so that the removal rate of chlorophyll is improved from 60 percent to 70 percent to 97 percent to 100 percent. The invention discloses anti-atherosclerosis application of the lignan monomer.

The invention belongs to the chemical medicine field, in particular to two anti-cancer medicine raw material compounds. The invention synthesizes several chemical raw materials to obtain novel 3- methoxy flavoine derivative-compound 5, 7-dihydroxy-8-(1, 1-dimethylaniline-3, 3', 4'- 3-methoxyflavone and compound 5, 7-dihydroxy-8-(1, 1-dimethylaniline-3, 4'- 2-methoxyflavone in four steps. The two compounds can reach the level of poly-methoxyl flavones (PMFS) compound which is separated from natural plants and poly-methylation flavones C-glycosylated derivative which are separated from medical plants, which have equal role and effect of inhibiting human tumor generation, play positive inhibition in anti-inflammatory diseases and anti-atherosclerosis diseases, and are two important raw materials of wide-spectrum antineoplastic medicines.

The invention discloses a traditional Chinese medicine compound preparation with an anti-atherosclerosis function. Red yeasts which can remove damp and phlegm and promote blood circulation to remove blood stasis and are warm in property, and herba gynostemmatis which can benefit qi, activate blood and remove phlegm and stasis and are cool in property, form a formula, so that the activities of the red yeasts and the herba gynostemmatis can generate a synergistic effect, the effects of harmonizing the body, regulating qi, reducing phlegm and removing stasis are enhanced, and the anti-atherosclerosis effect is enhanced. In order to further improve the drug effect of the traditional Chinese medicine compound preparation, fermented medicinal functional red yeasts and extracted herba gynostemmatis total glycosides can be selected and used to form a formula, and pharmaceutically acceptable auxiliary materials are adopted for preparing an oral preparation. An animal experiment shows that the compound preparation has a very good synergistic effect; and compared with single use of the red yeasts or the herba gynostemmatis total glycosides, the compound preparation has a more remarkable treatment effect. In addition, the traditional Chinese medicine compound preparation is free of toxic and side effects, good in tolerance, low in price and suitable for long-term treatment.